Botulinum Toxin-A for Hidradenitis Suppurativa

Botulinum Toxin-A for Hidradenitis Suppurativa

The purpose of this research study is to determine if the medication Botulinum Toxin-A (BTX-A) is effective in treating hidradenitis suppurativa (HS)

Hidradenitis suppurativa (HS) is an auto-inflammatory disorder of apocrine sweat glands which results in painful, draining nodules within hair-bearing skin of the axillae, groin, and perineum. There is no consensus for treatment of HS and neither a medical nor surgical cure exists. Several case reports show potential efficacy of Botulinum Toxin-A (BTX-A) in inducing remission of HS however, these studies are underpowered. The objective of this study is to determine if Botulinum Toxin- A induces regression, remission, or relapse of hidradenitis suppurativa lesions.

Inclusion Criteria:

• Subjects with active axillary hidradenitis suppurativa of the same severity bilaterally. regimen
• For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
• Agreement to forego other treatments for hidradenitis for the duration of the study

Exclusion Criteria:

• Current use of antibiotics, hormonal therapies, steroids, and/or biologics
• Presence of cardiac pacemaker
• Pregnancy or lactation
• Known neuromuscular disorder
• Known hyperhidrosis
• Febrile illness within one month
• Treatment with another investigational drug or other intervention within three months
• Patients without active axillary hidradenitis suppurativa